{
    "clinical_study": {
        "@rank": "62188", 
        "arm_group": [
            {
                "arm_group_label": "Co-Ad Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive one dose of the HZ/su study vaccine and one dose of Pneumovax 23 during the first visit and a second dose of HZ/su study vaccine during the third visit, two months later."
            }, 
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive all vaccines separately: one dose of the Pneumovax 23 vaccine at the first visit, one dose of the HZ/su study vaccine at the third visit and a second dose of the HZ/su study vaccine at the fourth visit, all two months apart."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the\n      GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with\n      Pneumovax 23\u2122 vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on\n      Pneumovax 23\u2122 vaccine immune response will also be evaluated."
        }, 
        "brief_title": "Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23\u2122 in Adults Aged 50 Years and Older", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Herpes Zoster", 
        "condition_browse": {
            "mesh_term": "Herpes Zoster"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who, in the opinion of the investigator, can and will comply with the\n             requirements of the protocol.\n\n          -  A male or female aged 50 years or older at the time of the first vaccination with the\n             study vaccine(s).\n\n          -  Written informed consent obtained from the subject.\n\n          -  Female subjects of non-childbearing potential may be enrolled in the study.\n\n               -  Non-childbearing potential is defined as pre-menarche, current tubal ligation,\n                  hysterectomy, ovariectomy or post-menopause.\n\n          -  Female subjects of childbearing potential may be enrolled in the study, if the\n             subject:\n\n               -  has practiced adequate contraception for 30 days prior to vaccination, and\n\n               -  has a negative pregnancy test on the day of vaccination, and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 2 months after completion of the vaccination series.\n\n        Exclusion Criteria:\n\n          -  Use of any investigational or non-registered product other than the study vaccines\n             within 30 days preceding the first dose of study vaccine, or planned use during the\n             study period.\n\n          -  Chronic administration of immunosuppressants or other immune-modifying drugs within\n             six months prior to the first vaccine dose. A prednisone dose of < 20 mg/day is\n             allowed. Inhaled, topical and intra-articular corticosteroids are allowed.\n\n          -  Administration or planned administration of a vaccine not foreseen by the study\n             protocol within the period starting 30 days before the first dose of study vaccine(s)\n             and ending 30 days after the last dose of study vaccine. This includes any type of\n             vaccine such as live, inactivated and subunit vaccines.\n\n          -  Administration of long-acting immune-modifying drugs within six months prior to the\n             first vaccine dose or expected administration at any time during the study period.\n\n          -  Concurrently participating in another clinical study, at any time during the study\n             period, in which the subject has been or will be exposed to an investigational or a\n             non-investigational vaccine/product.\n\n          -  Previous vaccination against Varicella-zoster virus (VZV) or HZ and/or planned\n             administration during the study of an HZ or VZV vaccine other than the study vaccine.\n\n          -  History of HZ.\n\n          -  History of documented pneumococcal infection within 5 previous years.\n\n          -  Prior receipt of any pneumococcal vaccine or planned use of this vaccine during the\n             study period, other than the study vaccine.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition resulting\n             from disease  or immunosuppressive/cytotoxic therapy .\n\n          -  History of any reaction or hypersensitivity likely to be exacerbated by any component\n             of the vaccines.\n\n          -  Acute disease and/or fever at the time of enrolment.\n\n               -  Fever is defined as temperature \u2265 37.5\u00b0C /99.5\u00b0F by oral route. The preferred\n                  route for recording temperature in this study will be oral.\n\n               -  Subjects with a minor illness (such as mild diarrhea, mild upper respiratory\n                  infection) without fever may, be enrolled at the discretion of the investigator.\n\n          -  Administration of immunoglobulins and/or any blood products within the 3 months\n             preceding the first dose of study vaccine or planned administration during the study\n             period.\n\n          -  Pregnant or lactating female.\n\n          -  Female planning to become pregnant or planning to discontinue contraceptive\n             precautions before 2 months after the last dose of study vaccine.\n\n          -  Any persons with cerebrospinal fluid (CSF) leaks, cochlear implants, chronic renal\n             failure, nephrotic syndrome, and functional or anatomic asplenia.\n\n          -  Any condition which, in the opinion of the investigator, prevents the subject from\n             participating in the study.\n\n          -  Any condition which, in the judgment of the investigator, would make intramuscular\n             (IM) injection unsafe."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "864", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02045836", 
            "org_study_id": "116889", 
            "secondary_id": "2012-005314-19"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Co-Ad Group", 
                    "Control Group"
                ], 
                "description": "2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.", 
                "intervention_name": "Herpes Zoster vaccine GSK 1437173A", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Co-Ad Group", 
                    "Control Group"
                ], 
                "description": "One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.", 
                "intervention_name": "Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23\u2122", 
                "intervention_type": "Biological", 
                "other_name": "Pneumo 23\u2122"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pneumovax 23", 
            "Co-administration", 
            "Herpes zoster", 
            "Immunogenicity", 
            "Safety", 
            "Adults"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Golden", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80401"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "67207"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbia", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21045"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Coquitlam", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V3K 3P4"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Truro", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B2N 1L2"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Sudbury", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "P3E 1H5"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Tartu", 
                        "country": "Estonia", 
                        "zip": "50106"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Estonia"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23\u2122 in Adults Aged 50 Years and Older", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Columbia: INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos)", 
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "-  Vaccine response rate for anti-gE antibody concentrations, as determined by enzyme-linked immunosorbent assay (ELISA), in subjects from the HZ/su - Pneumovax 23 Co-Ad group.", 
                "measure": "HZ/su immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "At one month post-dose 2 (Month 3)"
            }, 
            {
                "description": "-  Anti-gE antibody concentrations as determined by ELISA.", 
                "measure": "HZ/su immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "At one month post-dose 2 (Month 3 for the Co-Ad Group and Month 5 for the Control Group)"
            }, 
            {
                "description": "- Anti-pneumococcal antibody titers for the 12 following serotypes as determined by Opsonophagocytic Assay (OPA): 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.", 
                "measure": "Pneumococcal vaccine immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "At one month post-dose (Month 1)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02045836"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Occurrence of solicited local and general symptoms", 
                "safety_issue": "No", 
                "time_frame": "Within 7 days (Days 0-6) after each vaccination"
            }, 
            {
                "measure": "Occurrence of unsolicited Adverse Events (AEs)", 
                "safety_issue": "No", 
                "time_frame": "Within 30 days (Days 0 - 29) after each vaccination"
            }, 
            {
                "measure": "Occurrence of Serious Adverse Events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "During the entire study period (Month 0 - Month 14 for Co-Ad Group and Month 0 - Month 16 for the Control Group)"
            }, 
            {
                "description": "Occurrence and relationship to vaccination of any pIMDs", 
                "measure": "Occurrence of potential Immune Mediated Diseases (pIMDs)", 
                "safety_issue": "No", 
                "time_frame": "From first vaccination up to 30 days post last vaccination (Month 0 - Month 3 for the Co-Ad Group &amp; Month 0 - Month 5 for the Control Group)"
            }, 
            {
                "description": "Occurrence of any pIMDs", 
                "measure": "Occurrence of potential Immune Mediated Diseases (pIMDs)", 
                "safety_issue": "No", 
                "time_frame": "During the period starting after 30 days post last vaccination up to study end (Month 3 - Month 14 for the Co-Ad Group &amp; Month 5 - Month 16 for the Control Group)"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}